Final height in a patient with Laron syndrome after long-term therapy with rhIGF-I and short-term therapy with LHRH-analogue and oxandrolone during puberty

Journal of Endocrinological Investigation

Volumn 28, Issue 5, 2005, Pages 274-279

  Zucchini, S ^a   Scarano, E ^a   Baldazzi, L ^a   Mazzanti, L ^a   Pirazzoli, P ^a   Cacciari, E ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Child; GH deficiency; GH insensitivity syndrome

Indexed keywords

ESTRADIOL; GONADORELIN DERIVATIVE; OXANDROLONE; PROGESTERONE; RECOMBINANT SOMATOMEDIN C; TRIPTORELIN; ANABOLIC AGENT; DRUG DERIVATIVE; GONADORELIN; RECOMBINANT PROTEIN; SOMATOMEDIN C;

ANTHROPOMETRY; ARTICLE; BODY MASS; BONE AGE; CASE REPORT; FEMALE; GROWTH RATE; HUMAN; LARON SYNDROME; LONG TERM CARE; MUTATION; PUBERTY; AGE DETERMINATION; BODY HEIGHT; CHILD; PATHOLOGY; PHYSIOLOGY;

AGE DETERMINATION BY SKELETON; ANABOLIC AGENTS; ANTHROPOMETRY; BODY HEIGHT; BODY MASS INDEX; CHILD; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LARON SYNDROME; OXANDROLONE; PUBERTY; RECOMBINANT PROTEINS;

EID: 21444436202     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03345385     Document Type: Article

References (24)

1. Ranke M, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Horm Res 1999, 51: 128-34.
2. Backeljauw PF, Underwood LE, and the GHIS Collaborative Group. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 2001, 86: 1504-10.
3. Green H, Morikawa M, Nixon T. A dual effector theory of growth hormone action. Differentiation 1985, 29: 195-8.
4. Burren CP, Wanek D, Mohan S, Cohen P, Guevara-Aguirre J, Rosenfeld RG. Serum levels of insulin-like-growth-factor binding proteins in Ecuadorian children with growth hormone insensitivity. Acta Paediatr 1999, 428 (Suppl): 185-91.
5. Mauras N, Rogol AD, Haymond MW, Veldhuis JD. Sex steroids, growth hormone, insulin-like growth factor-I: neuroendocrine and metabolic regulation in puberty. Horm Res 1996, 45: 74-80.
6. Adashi EY, Resnick CE, Hernandez ER, et al. Insulin-like-growth-factor-I as an amplifier of follicle-stimulating hormone action: studies on mechanism(s) and site(s) of action in cultured rat granulose cells. Endocrinology 1988, 122: 1583-91.
7. Cassio A, Cacciari E, Balsamo A, Bal M, Tassinari D. Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years. Arch Dis Child 1999, 81: 329-32.
8. Maniati-Christidi M, Livadas S, Voutetakis A, Tolis G, Dacou-Voutetakis C. Human growth hormone and gonadotropin releasing hormone analog combination therapy increases predicted height in short normal girls. Clin Pediatr (Phila) 2003, 42: 59-65.
9. Yanovski JA, Rose SR, Municchi G, et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003, 348: 908-17.
10. Brook CG. Treatment of late puberty. Horm Res 1999, 51 3 (Suppl): 101-3.
11. Nilsson KO, Albertsson-Wikland K, Alm J, et al. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. J Clin Endocrinol Metab 1996, 81: 635-40.
12. Rosenfeld RG, Attie KM, Frane J, et al. Growth hormone therapy of Turner's syndrome: beneficial effect on adult height. J Pediatr 1998, 132: 319-24.
13. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976, 51: 170-9.
14. Cacciari E, Milani S, Balsamo A, et al. Italian cross-sectional growth charts for height, weight and BMI (6-20 y). Eur J Clin Nutr 2002, 56: 171-80.
15. Baumbach L, Schiavi A, Bartlett R, et al. Clinical, biochemical, and molecular investigations of a genetic isolate of growth hormone insensitivity (Laron's syndrome). J Clin Endocrinol Metab 1997, 82: 444-51.
16. Prader A, Layo RH, Molinari L, Issler C. Physical growth of Swiss children from birth to 20 years of age. Helv Paediatr Acta 1989, 52 (Suppl): 1-25.
17. Laron Z, Lilos P, Klinger B. Growth curves for Laron syndrome. Arch Dis Child 1993, 68: 768-70.
18. Martinez V, Vasconez O, Martinez AL, et al. Body changes in adolescent patients with growth hormone receptor deficiency receiving recombinant human insulin-like growth factor I and luteinizing hormone-releasing hormone analogue: preliminary results. Acta Paediatr 1994, 399 (Suppl): 133-6.
19. Van der Eerden BC, Karperien M, Wit JM. Systemic and local regulation of the growth plate. Endocr Rev 2003, 24: 782-801.
20. Woods KA, Dastot F, Preece MA, et al. Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1997, 82: 3529-35.
21. Messina MF, De Luca F, Wasniewska M, Valenzise M, Lombardo F, Ghizzoni L. Final height in isolated GH deficiency type 1A: effects of 5-year treatment with IGF-I. Eur J Endocrinol 2001, 144: 379-83.
22. Darendeliler F, Hindmarsh PC, Preece MA, Cox L, Brook CG. Growth hormone increases rate of pubertal maturation. Acta Endocrinol (Copenh) 1990, 122: 414-6.
23. Laron Z, Klinger B. Effect of insulin-like growth factor-1 treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance). Eur J Endocrinol 1998, 138: 176-80.
24. Walker JL, Crock PA, Behncken SN, et al. A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analogue. J Clin Endocrinol Metab 1998, 83: 2554-61.